Compare FWRD & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FWRD | MYGN |
|---|---|---|
| Founded | 1981 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 708.1M | 625.5M |
| IPO Year | 1993 | 1995 |
| Metric | FWRD | MYGN |
|---|---|---|
| Price | $25.03 | $6.95 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 12 |
| Target Price | ★ $33.67 | $11.82 |
| AVG Volume (30 Days) | 567.3K | ★ 1.1M |
| Earning Date | 11-05-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,496,734,000.00 | $825,300,000.00 |
| Revenue This Year | $3.18 | $0.10 |
| Revenue Next Year | $4.39 | $5.28 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 14.54 | 0.21 |
| 52 Week Low | $9.79 | $3.76 |
| 52 Week High | $35.47 | $15.47 |
| Indicator | FWRD | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 61.67 | 45.11 |
| Support Level | $25.31 | $7.15 |
| Resistance Level | $26.70 | $7.43 |
| Average True Range (ATR) | 1.05 | 0.30 |
| MACD | 0.15 | -0.01 |
| Stochastic Oscillator | 74.00 | 3.81 |
Forward Air Corp is an asset-light freight and logistics company. The company's operating segment includes Expedited Freight, Omni Logistics, and Intermodal and Corporate. The company generates maximum revenue from the Omni Logistics segment. The expedited Freight segment operates a comprehensive national network to provide expedited regional, inter-regional, and national LTL (less-than-truckload) services. It also offers customers local pick-up and delivery and other services including final mile, truckload, shipment consolidation and deconsolidation, warehousing, customs brokerage, and other handling. The Company conducts business in the United States, Canada, and Mexico.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.